What you should know about taking Wegovy for fatty liver disease

When the FDA approves a medication to treat a specific condition, that isn’t always the end of the story. Sometimes the drug proves effective at treating other health issues, and so the FDA adds to its approved uses. That’s what happened with Wegovy (a brand name of semaglutide). It was FDA-approved for chronic weight management in 2021, but then got an additional approval in August 2025 to treat MASH, or metabolic dysfunction-associated steatotic liver disease. That decision, say clinicians, has opened up treatment options for MASH in a really exciting way. 

If you are living with MASH, keep reading to learn more about how Wegovy for fatty liver works, what the medication can’t do, and why lifestyle changes are still a cornerstone in treatment. 

Key takeaways

• In 2025 the FDA granted accelerated approval of Wegovy (semaglutide) for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis. The approval is based on surrogate endpoints (how well the liver improves after a set amount of time) as opposed to long-term results (those trials are ongoing).

• Research shows that Wegovy can significantly improve liver fibrosis and resolve steatohepatitis better than placebo.

• Wegovy may reduce fat in the liver through weight loss, and the drug may have a direct effect on liver cells themselves, such as by reducing inflammation.

• The medication is not right for everyone with fatty liver disease — it is only for people who fit a specific MASH profile. Connect with a clinician who can evaluate your eligibility for the medication, as well as recommend lifestyle changes to improve overall metabolic function.

First, let’s talk about what Wegovy is: a GLP-1 medication approved to treat certain health conditions when paired with a reduced calorie diet and exercise. In 2021, the FDA approved Wegovy for chronic weight management in adults with obesity or those who have overweight and a weight-related comorbidity. Three years later, in 2024, Wegovy’s label was expanded and was then approved to reduce the risk of cardiovascular events in adults with overweight or obesity (this came after additional clinical trials).

In August 2025, the FDA granted accelerated approval of Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis (stage F2-F3) — the first GLP-1 approval for MASH and the second drug ever approved to treat the disease.

Noncirrhotic MASH refers to MASH that has not progressed to cirrhosis, which is permanent scarring that injures the liver and affects its functioning. Liver fibrosis is scarring and it's broken up into five stages, F0 (no scarring) to F4 (cirrhosis). Stages F2 and F3, which is what Wegovy is approved to treat, are moderate and advanced scarring, respectively.

The colloquial term, “fatty liver” is a casual, umbrella term for a group of liver diseases that includes MASLD and MASH. In fact, the names for liver disease changed in 2023 to be more affirmative and non-stigmatizing:

• Nonalcoholic fatty liver disease (NAFLD) is now called metabolic dysfunction-associated steatotic liver disease (MASLD).

• Nonalcoholic steatohepatitis (NASH) is now called metabolic dysfunction-associated steatohepatitis (MASH). 

MASLD is the most common chronic liver disease in the world, and more than 30% of people have the disease. For those with MASLD, a significant portion will go on to develop MASH, a more severe and aggressive form of the disease. MASH can further progress to fibrosis (a build up of scar tissue) and liver cancer (hepatocellular carcinoma) in some people.

There are many health benefits of GLP1-s. When it comes to Wegovy as a treatment for MASH, you can broadly think about the benefits in two ways, says Dr. Arun Sanyal, M.D., director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University in Richmond. Some benefits come directly from the fact that people lose weight while taking Wegovy, and some come from the impact of the medication on the liver.

Can improve liver fibrosis and resolve steatohepatitis

Based on the phase 3 ESSENCE trial published in The New England Journal of Medicine, patients taking semaglutide 2.4 mg for 72 weeks had significantly improved liver fibrosis (scarring) and resolved steatohepatitis (the fat build-up). 

How semaglutide targets MASH isn’t entirely clear, says Sanyal, who was a co-author of the ESSENCE trial. “Recent data shows that it may work through special cells in the liver,” he says. Liver cells may have receptors for GLP-1, some research suggests, and semaglutide may also affect inflammatory and metabolic pathways that — indirectly — affect liver tissue to treat fibrosis.

Drives weight loss that targets the metabolic root

Wegovy was first approved for weight loss, so it makes sense that people taking it for MASH would lose weight. People in the ESSENCE trial had about a 10.5% weight loss, while those in the placebo group lost 2% of their body weight. Wegovy causes weight loss by reducing your appetite, helping you consume fewer calories. 

And weight loss has a direct connection to your liver health. “When we reduce body fat, we reduce liver fat,” says cardiologist Dr. Ian Neeland, M.D., director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute in Ohio. “When you eat less, you feed less triglycerides to the liver,” he says. (Triglycerides come from dietary fat, and your body stores excess in its fat cells.) 

Treats the whole metabolic picture 

The fact that Wegovy treats multiple interconnected health conditions is what makes it such a landmark drug, says Sanyal. Wegovy has already shown that it improves body weight, cardiovascular health, sleep apnea, and osteoarthritis — and now, MASH. Since people who have liver disease may have the comorbid conditions listed above, treatment with Wegovy can make a big impact on your overall health. “You’re hitting multiple chronic risks to life with one drug,” Sanyal says.

Clinicians are excited about Wegovy as a treatment for some patients with MASH, but it’s not appropriate for everyone — and lifestyle changes remain an important part of therapy. Here are its limitations.  

It’s not for simple fatty liver or more advanced cirrhosis

Wegovy is not FDA-approved to treat MASLD, the less serious form of fatty liver disease. That said, MASLD often occurs alongside obesity, diabetes, or sleep apnea — and semaglutide (the active ingredient in Wegovy) is approved to treat these conditions. “Taking semaglutide in these cases may also improve liver fat, but this is more theoretical because we don’t have longitudinal [long-term] studies to show this,” says Sanyal. 

The clinical trials for this drug looked at MASH with fibrosis in stage 2 or 3. If you have cirrhosis (permanent liver scarring), which is a more advanced liver disease, the medication may not be as effective, says Sanyal. “Plus, when you lose weight, you also lose lean body mass. Patients with cirrhosis need muscle to buffer the loss of liver function.”  

It doesn’t have long-term data yet

Wegovy had what’s known as an accelerated approval for treating MASH. This kind of approval rests on surrogate endpoints, meaning the FDA looks at indicators or signs that the treatment works on the condition. This allows drugs to be approved faster, which is critical when you’re talking about any disease that can become life-threatening, like MASH. But that also means that it gets approved before there’s long-term data on clinical outcomes, like liver failure and surrival. These studies are being performed right now, and once the results come in, clinicians will have a better idea of how this drug can change the course of disease or improve quality of life or overall functioning.

It’s not a substitute for lifestyle change

MASH can improve or be resolved by losing 10% of your body weight, which can be given an assist with medication or procedures like bariatric surgery. But even so, don’t discount the importance of having healthy habits. “Lifestyle is a cornerstone of metabolic health,” says Neeland. In the phase 3 ESSENCE trial, Wegovy was paired with lifestyle changes like a reduced calorie diet and increased exercise.  

Weight Watchers can help you with the habits piece of the puzzle. You get a complete lifestyle program designed to help you prioritize eating well, moving more, and taking care of your overall well-being.

As a GLP-1 medication, Wegovy can support diet change because the medication helps decrease your appetite. “Some studies show that GLP-1s help people change their attitudes, habits, and choices around food they want to eat,” Neeland says. Med+ member data bears that out: Those prescribed a GLP-1 and following the lifestyle program didn’t just lose weight, they improved their diet quality by 34.7% and increased their number of strength-training days by 53.2%.*

In addition to diet and exercise, it’s also important to get good sleep and address any mental health issues, such as anxiety or depression, adds Sanyal. Sleep affects hunger and your motivation to exercise, while mental health also plays a role in overeating for some people. 

It’s not for everyone

Some people are not good candidates for Wegovy: Those who have a personal or family history of medullary thyroid carcinoma or who have multiple endocrine neoplasia syndrome type 2 should not take it. Other conditions, such as problems with your pancreas or kidneys, warrant a conversation with your provider before taking Wegovy.

Wegovy 2.4 mg for MASH requires a clinician evaluation, diagnosis, and prescription. Your clinician will evaluate your goals, provide lifestyle recommendations and guidance, follow your progress, and address side effects and safety.

GLP-1s may get the most attention for their impact on weight, but their impact on the liver further proves that these medications’ real power are in how they improve your health. Although weight loss is a key component of the health impact of these medications, the scale isn’t the entire story. GLP-1 drugs have been shown to have a therapeutic effect on type 2 diabetes, obesity, cardiovascular health, obstructive sleep apnea, chronic kidney disease, and more. They do this by reducing inflammation, activating GLP-1 receptors throughout multiple organs, and lowering blood glucose levels and weight.

While Wegovy may be able to help certain people improve their liver health, many people don’t need medication to make a difference. A 5 to 10% weight loss may meaningfully improve metabolic health, including the health of your liver. That can be done through lifestyle changes like Mediterranean-style eating, consuming less added sugar and alcohol, and getting regular activity — all goals that can be supported with the Weight Watchers Core+ Program. 

Some people may experience certain side effects on Wegovy, including (in no particular order):

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Stomach pain

While they are less common, Wegovy also comes with a risk for more serious side effects, including:

• Pancreatitis (inflammation of the pancreas)

• Kidney problems

• Gallbladder problems

• Hypoglycemia (low blood sugar)

• Hypersensitivity reactions (such as rash, hives, or difficulty breathing)

Bring up any side effects with your clinician as they can offer recommendations or tweak your dose to help improve them. A full list of side effects can be found on the Wegovy site.

Wegovy (semaglutide 2.4 mg) is FDA-approved for treating MASH with stage 2 and 3 liver fibrosis. The medication may work directly on the liver, as well as indirectly through weight loss to improve metabolic health. It’s not for everyone, however, so talk to your clinician about an evaluation and if this medication is a good option for you.